These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32098624)

  • 1. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
    Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
    Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
    Dawwas GK; Hennessy S; Brensinger CM; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Aquilante CL; Kimmel SE; Leonard CE
    Clin Pharmacol Ther; 2022 Jan; 111(1):227-242. PubMed ID: 34331322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations.
    Dhopeshwarkar N; Brensinger CM; Bilker WB; Soprano SE; Flory JH; Dawwas GK; Gagne JJ; Hennessy S; Leonard CE
    Sci Rep; 2020 Jun; 10(1):10070. PubMed ID: 32572080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
    Wang JL; Dong YH; Ko WC; Chang CH; Wu LC; Chuang LM; Chen PC
    Diabetes Obes Metab; 2018 Dec; 20(12):2811-2820. PubMed ID: 29974616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
    Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
    Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
    Breunig IM; Shaya FT; McPherson ML; Snitker S
    J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
    Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
    Hsu JC; Ross-Degnan D; Wagner AK; Zhang F; Lu CY
    Clin Ther; 2015 Jul; 37(7):1420-1432.e1. PubMed ID: 25976425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
    Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
    Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 diabetes-A nationwide cohort study.
    Hsieh YC; Liao YC; Li CH; Lin JC; Weng CJ; Lin CC; Lo CP; Huang KC; Huang JL; Lin CH; Wang JS; Wu TJ; Sheu WH
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3226. PubMed ID: 31655001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.
    Dore DD; Trivedi AN; Mor V; Lapane KL
    Pharmacotherapy; 2009 Jul; 29(7):775-83. PubMed ID: 19558251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Tunis SL; Minshall ME; St Charles M; Pandya BJ; Baran RW
    Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
    Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
    Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
    Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.